Diagnostics industry demands finance reform
This article was originally published in Clinica
Executive Summary
The German industry association for diagnostics (VDGH) and the professional laboratory doctors' association (BDL) last week backed calls by the federal association of statutory health insurance physicians (KBV) to promote the optimal use of laboratory diagnostics in healthcare. In a joint enquiry entitled, "laboratory doctor 2001", VDGH and BDL said that financial pressures and restrictive budgets had led to insecurity in the doctors' profession and this is harming patients.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.